AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Multimodal AI Predicts High-risk Pathology in Lung Cancer Associated With Cystic Airspaces

Recruitingn/aAges 18 Years - anyAllCentral South University
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to develop and validate an artificial intelligence (AI)-based multimodal radiomics model that integrates preoperative CT imaging features and clinical data to predict pathological high-risk features in patients with lung cancer associated with cystic airspaces (LCCA). The main questions it aims to answer are: Can an AI-based multimodal radiomics model accurately predict pathological high-risk features in LCCA before surgery? Does the integration of CT imaging features and clinical variables improve preoperative risk stratification compared with imaging or clinical information alone?

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: * 1\. Patients with non-small cell lung cancer (NSCLC) confirmed by biopsy or postoperative pathological examination. 2\. Patients who underwent surgical resection of a pulmonary tumor, including lobectomy, segmentectomy, or wedge resection. 3\. Patients with complete preoperative chest CT imaging data. 4. Patients whose preoperative chest CT showed a well-defined air-containing cystic component within the tumor, consistent with the radiological features of lung cancer associated with cystic airspaces (LCCA). 5\. Patients with available clinical and pathological data required for analysis. Exclusion Criteria: * 1\. Patients with a history of pulmonary diseases that may cause cystic lung lesions, such as pulmonary tuberculosis, pulmonary fungal infection, lymphangioleiomyomatosis (LAM), or Birt-Hogg-Dubรฉ (BHD) syndrome. Emphysema will not be considered an exclusion criterion; however, patients with severe emphysema will be excluded if it significantly affects the identification, boundary delineation, or imaging feature assessment of the target lesion. 2\. Patients who received systemic antitumor therapy before enrollment, including chemotherapy, radiotherapy, targeted therapy, or immunotherapy. 3\. Patients with other primary malignancies. 4. Patients with missing preoperative chest CT images or CT images of insufficient quality for analysis. 5\. Patients without a definite pathological diagnosis or with incomplete pathological results. 6\. Patients with missing clinical data.
๐Ÿ’Š

What it tests

  • Not listed
๐Ÿ“

Where

1 site
The Second Xiangya Hospital of Central South University
Changsha, China
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy